Red Blood Cell Transfusion — Competitive Intelligence Brief

Red Blood Cell Transfusion (Red Blood Cell Transfusion) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Blood product / Cellular therapy. Area: Hematology / Critical Care.

marketed Blood product / Cellular therapy Hematology / Critical Care Biologic

Target snapshot

Red Blood Cell Transfusion (Red Blood Cell Transfusion) — Rutgers, The State University of New Jersey. Red blood cell transfusion restores oxygen-carrying capacity by increasing circulating hemoglobin and red blood cell count in anemic or hemorrhaging patients.

Comparator set (4 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Red Blood Cell Transfusion TARGET	Red Blood Cell Transfusion	Rutgers, The State University of New Jersey	marketed	Blood product / Cellular therapy
Liquid-stored platelets	Liquid-stored platelets	Australian and New Zealand Intensive Care Research Centre	phase 3	Blood product / Cellular therapy
Deep-frozen platelets	Deep-frozen platelets	Alrijne Ziekenhuis Leiderdorp	phase 3	Blood product / Cellular therapy
Liberal Red blood cell transfusion	Liberal Red blood cell transfusion	Assistance Publique - Hôpitaux de Paris	phase 3	Blood product / Cellular therapy
Cryopreserved platelets	Cryopreserved platelets	Australian and New Zealand Intensive Care Research Centre	phase 3	Blood product / Cellular therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Blood product / Cellular therapy class)

1. Australian and New Zealand Intensive Care Research Centre · 2 drugs in this class
2. Alrijne Ziekenhuis Leiderdorp · 1 drug in this class
3. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
4. Rutgers, The State University of New Jersey · 1 drug in this class